Propella Acquisition To Shore Up Astellas’s Prostate Cancer Presence
Advantages Seen Over Zytiga
Astellas makes targeted acquisition of small, private US venture in apparent move to shore up its prostate cancer franchise amid a looming major patent expiry.
